Previous Article | Next Article ![]()
Infection and Immunity, May 2001, p. 3507-3509, Vol. 69, No. 5
Section of Rheumatology, Department of Internal Medicine,
Yale University School of Medicine, New Haven, Connecticut
065201; Laboratory of Human Bacterial
Pathogenesis, Rocky Mountain Laboratories, National Institute of
Allergy and Infectious Diseases, National Institutes of Health,
Hamilton, Montana 598402; and Center for
Comparative Medicine, Schools of Medicine and Veterinary Medicine,
University of California, Davis, California 956163
Received 12 October 2000/Returned for modification 18 December
2000/Accepted 21 February 2001
Clonal Borrelia burgdorferi N40 (cN40) passaged 75 times in vitro (N40-75) infects mice but does not cause disease. N40-75 passaged 45 times further in vitro (N40-120) was no longer infectious and lacked genes encoded on linear plasmids 38 and 28-1, among other
differences. These data suggest that B. burgdorferi cN40, N40-75, and N40-120 have distinct phenotypes that can be used to
dissect the genetic elements responsible for pathogenicity and infectivity.
Lyme borreliosis, which is caused by
Borrelia burgdorferi, can result in infection and disease
involving the skin, joints, and heart, both in humans and in
experimental models (2, 3, 18, 27). Comparisons of
B. burgdorferi isolates cultured in vitro have helped
to identify B. burgdorferi genes that may be associated
with infectivity. Noninfectious B. burgdorferi isolates have been shown to lack, or have reduced expression of or
mutations in, ospB, ospD, ospC, or vls, among
other genes, and the loss of several plasmids, including linear plasmid
(lp) 25, lp28.4, and circular plasmid 9 (5, 16, 19, 20, 24, 25,
28, 31-34). A direct cause and effect relationship has not yet
been established for any single gene or plasmid: for example, some noninfectious B. burgdorferi B31 clones express
ospD and other infectious clones do not (15,
19-21). Recent studies have also suggested an important role
for lp28-1 in B. burgdorferi infectivity (14,
22). The genetic factors that contribute to B. burgdorferi infectivity and pathogenicity (i.e., the ability to
cause arthritis and carditis) are likely to be both multifactorial and distinct.
Several B. burgdorferi isolates that were initially
nonclonal have been shown to lose infectivity fairly quickly upon in
vitro passage (19, 20, 25). In contrast, a clonal isolate
of B. burgdorferi N40 (cN40) that is highly pathogenic
in C3H/HeN (C3H) mice, causing severe arthritis and carditis, retains
infectivity after multiple passages (1). However, cN40
passaged 75 times in vitro (N40-75) and individual N40-75 clones were
infectious but nonpathogenic in mice, thereby enabling us to begin to
dissociate these two processes (1). N40-75 also remained
nonpathogenic when passaged one time through immunocompetent mice (data
not shown), but the stability of this phenotype in vivo must be
explored further, because N40-75 can cause disease in severe combined
immunodeficient (SCID) mice (1). The inability of N40-75
to cause arthritis and carditis in immunocompetent mice has been
associated with the lack of expression of several genes that are
preferentially expressed in vivo rather than the loss of specific
genetic material in DNA analyses or of antigens in protein profiles or
immunoblots (1). We have now passaged N40-75 further to
develop specific derivatives of the spirochete that are
noninfectious in mice and that can be used to understand the
differences that contribute to both the infectivity and pathogenicity
of B. burgdorferi.
N40-75 passaged in vitro retained infectivity in C3H mice until passage
120 (N40-120). Spirochetes were passaged by cultivation in
Barbour-Stoenner-Kelly II medium as described previously
(1). Every five passages, the spirochetes were tested for
their ability to infect mice; representative passaged isolates (i.e.,
N40-90, N40-105, and N40-120) are shown in Table
1. When B. burgdorferi was noted to lose infectivity (N40-120), the previous five individual passaged isolates were then also tested for infectivity, such as
N40-119 (Table 1). Mice were intradermally inoculated with 104 N40-120 spirochetes in the dorsal midthorax, and 2 weeks later, skin, bladder, heart, and joints were examined for
B. burgdorferi by using PCR, culture, and
histopathology (Table 1) (1). Infection or
disease was not evident in mice challenged with N40-120. Five individual N40-120 clones were also noninfectious in mice (data not
shown). N40-120 remained noninfectious even when 107
organisms were injected into C3H mice or when spirochetes were administered to immunodeficient C3H-scid mice.
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.5.3507-3509.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Dissociation of Infectivity and Pathogenicity in
Borrelia burgdorferi
![]()
ABSTRACT
Top
Abstract
Text
References
![]()
TEXT
Top
Abstract
Text
References
TABLE 1.
Noninfectious derivatives of B. burgdorferi N40
To identify the factors that correlate with infectivity of N40-120,
protein profiles of cN40 and N40-120 were compared (Fig. 1A). Previous studies have demonstrated
that consistent differences between cN40 and N40-75 were not apparent
from sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) or immunoblotting, in part because subclones of N40-75 had
variable patterns of protein expression (1). Several
protein bands were somewhat less intense in N40-120 than in cN40 on
Coomassie blue-stained SDS-12% PAGE gels (Fig. 1A). In addition, cN40
had several bands between 26 to 35 kDa that were not as evident in
N40-120 upon immunoblotting using sera from
B. burgdorferi cN40-infected mice (Fig. 1B). These studies suggested that specific genetic elements might have been lost in N40-120.
|
PCR of selected B. burgdorferi genes demonstrated the loss of some genes that are either antigenic or have been associated with infectivity. PCR was performed for 30 cycles with primers specific for each gene, as described previously (1). Several genes, including ospA (which is down-regulated during tick engorgement [6, 8]), ospC (which is up-regulated during tick feeding [26]), bbk50 (which is preferentially expressed in vivo [11]), flaB (which is involved in skeletal structure and motility [17]), and p21 (a member of the ospE-related protein [erp] gene family [7]), were present in cN40, N40-75, and N40-120 (Fig. 1C). The amplified p21 PCR product was lower in intensity in cN40 than in N40-120 but was always detectable in repeated assays. The ospD gene, which is on lp38 and encodes a 28-kDa protein, was not present in N40-120 (Fig. 1C). bbj25 and bbj48 (13), which are two additional genes on lp38, were also not evident in N40-120, suggesting that this plasmid had been lost in N40-120 (Fig. 1C). Previous studies have shown that infectivity does not correlate strictly with the presence of ospD (15, 19-21). We therefore assessed whether erpT, a gene that is preferentially expressed in deep tissues and is present on the vls-containing plasmid lp28-1, was present in N40-120 (10, 12, 13). erpT DNA was not detected in N40-120 (Fig. 1C). The vls locus has been strongly correlated with infectivity (33, 34), and Southern blotting revealed that N40-120 lacked the vls gene locus, which is consistent with the loss of lp28-1 (Fig. 1D). PCR and Southern blotting demonstrated that N40-119 contained genes located on lp28-1 and lp38 (results not shown), indicating that these two plasmids were lost during the subsequent passage. These data provide initial insight into some of the genetic differences between cN40 and N40-120, but they are not meant to be comprehensive.
We have demonstrated that passaged isolates of B. burgdorferi N40
cN40, N40-75, and N40-120
can be distinguished
with respect to infectivity and pathogenicity. The number of passages
required to generate N40 spirochetes with alterations in infectivity
suggests that previously infectious organisms can be converted into
noninfectious spirochetes by the loss of genetic material but that
conversion does not occur equally during all passages. These
B. burgdorferi N40 descendants may provide new
opportunities for targeted genetic manipulation of the spirochete that
can then be studied in the murine model. Initial studies have
demonstrated that cN40 and infectious clones derived from cN40 can be
transformed by electroporation, although the frequency of
transformation was approximately 100-fold lower than what was observed
with a noninfectious clone of B. burgdorferi B31 (P. Rosa, unpublished results). Transformation of B. burgdorferi has previously only been demonstrated in noninfectious B. burgdorferi B31 (4, 9, 23, 29).
Recently, Stewart and his colleagues succeeded in transforming
infectious spirochetes with a shuttle vector capable of autonomous
replication in B. burgdorferi (30). These
developments should facilitate efforts to define the contributions of
specific B. burgdorferi genes to infection and disease.
The factors contributing to the ability of B. burgdorferi to infect the mammalian host and to cause specific disease manifestations, such as arthritis and carditis, are likely to be multifactorial. Both the diversity of the host response to the spirochete and the virulence of the incoming B. burgdorferi isolate may influence the outcome of exposure to this pathogen. B. burgdorferi cN40, N40-75, and N40-120 have well-defined phenotypes in the experimental murine model of Lyme disease. These organisms should prove useful for distinguishing the spirochete genotypes that are important for B. burgdorferi persistence throughout its life cycle and for the ability of this organism to cause disease that affects selected organ systems.
| |
ACKNOWLEDGMENTS |
|---|
Grants from the National Institutes of Health, Arthritis Foundation, and American Heart Association and a gift from SmithKline Beecham Biologicals supported this work. E. Fikrig is the recipient of a Burroughs Wellcome Clinical Scientist Award in Translational Research.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Yale University School of Medicine, Section of Rheumatology, Department of Internal Medicine, 608 Laboratory of Clinical Investigation, P.O. Box 208031, New Haven, CT 06520-8031. Phone: (203) 785-2453. Fax: (203) 785-7053. E-mail: erol.fikrig{at}yale.edu.
Editor: R. N. Moore
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Anguita, J.,
S. Samanta,
B. Revilla,
K. Suk,
S. Das,
S. W. Barthold, and E. Fikrig.
2000.
Borrelia burgdorferi gene expression in vivo and spirochete pathogenicity.
Infect. Immun.
68:1222-1230 |
| 2. | Barthold, S. W., D. S. Beck, G. M. Hansen, G. A. Terwilliger, and K. D. Moody. 1990. Lyme borreliosis in selected strains and ages of laboratory mice. J. Infect. Dis. 162:133-138[Medline]. |
| 3. | Barthold, S. W., D. H. Persing, A. L. Armstrong, and R. A. Peeples. 1991. Kinetics of Borrelia burgdorferi: dissemination and evolution of disease following intradermal inoculation of mice. Am. J. Pathol. 163:263-273. |
| 4. |
Bono, J. L.,
A. F. Elias,
J. J. Kupko,
B. Stevenson,
K. Tilly, and P. Rosa.
2000.
Efficient targeted mutagenesis in Borrelia burgdorferi.
J. Bacteriol.
182:2445-2452 |
| 5. | Carroll, J. A., and F. C. Gherardini. 1996. Membrane protein variations associated with in vitro passage of Borrelia burgdorferi. Infect. Immun. 64:392-398[Abstract]. |
| 6. | Coleman, J. L., J. A. Gebbia, J. Piesman, J. L. Degen, T. H. Bugge, and J. L. Benach. 1997. Plasminogen is required for efficient dissemination of Borrelia burgdorferi in ticks and for enhancement of spirochetemia in mice. Cell 89:1111-1119[CrossRef][Medline]. |
| 7. | Das, S., S. W. Barthold, S. S. Giles, R. R. Montgomery, S. R. Telford, and E. Fikrig. 1997. Temporal pattern of Borrelia burgdorferi p21 expression in ticks and the mammalian host. J. Clin. Investig. 99:987-995[Medline]. |
| 8. |
de Silva, A. M.,
S. R. Telford,
L. R. Brunet,
S. W. Barthold, and E. Fikrig.
1996.
Borrelia burgdorferi OspA is an arthropod-specific transmission-blocking Lyme disease vaccine.
J. Exp. Med.
183:271-275 |
| 9. |
Elias, A. F.,
J. L. Bono,
J. A. Carroll,
P. Stewart,
K. Tilly, and P. Rosa.
2000.
Altered stationary-phase response in a Borrelia burgdorferi rpoS mutant.
J. Bacteriol.
182:2909-2918 |
| 10. |
Feng, S.,
E. Hodzic, and S. W. Barthold.
2000.
Lyme arthritis resolution with antiserum to a 37-kilodalton Borrelia burgdorferi protein.
Infect. Immun.
68:4169-4173 |
| 11. | Fikrig, E., S. W. Barthold, W. Sun, W. Feng, S. R. Telford, and R. A. Flavell. 1997. Borrelia burgdorferi P35 and P37 proteins, expressed in vivo, elicit protective immunity. Immunity 6:531-539[CrossRef][Medline]. |
| 12. | Fikrig, E., M. Chen, S. W. Barthold, J. Anguita, W. Feng, S. R. Telford, and R. A. Flavell. 1999. Borrelia burgdorferi erpT expression in the arthropod vector and murine host. Mol. Microbiol. 31:281-290[CrossRef][Medline]. |
| 13. | Fraser, C. M., S. Casjens, W. M. Huang, G. G. Sutton, R. Clayton, R. Lathigra, O. White, K. A. Ketchum, R. Dodson, E. K. Hickey, M. Gwinn, B. Dougherty, J. F. Tomb, R. D. Fleischmann, D. Richardson, J. Peterson, A. R. Kerlavage, J. Quackenbush, S. Salzberg, M. Hanson, R. van Vugt, N. Palmer, M. D. Adams, J. Gocayne, J. C. Venter, et al. 1997. Genomic sequence of a Lyme disease spirochaete, Borrelia burgdorferi. Nature 390:580-586[CrossRef][Medline]. |
| 14. |
Labandeira-Rey, M., and J. T. Skare.
2001.
Decreased infectivity in Borrelia burgdorferi strain B31 is associated with loss of linear plasmid 25 or 28-1.
Infect. Immun.
69:446-455 |
| 15. |
Marconi, R. T.,
D. S. Samuels,
R. K. Landry, and C. F. Garon.
1994.
Analysis of the distribution and molecular heterogeneity of the ospD gene among the Lyme disease spirochetes: evidence for lateral gene exchange.
J. Bacteriol.
176:4572-4582 |
| 16. | Masuzawa, T., T. Kurita, H. Kawabata, and Y. Yanagihara. 1994. Relationship between infectivity and OspC expression in Lyme disease Borrelia. FEMS Microbiol. Lett. 123:319-324[CrossRef][Medline]. |
| 17. |
Motaleb, M. A.,
L. Corum,
J. L. Bono,
A. F. Elias,
P. Rosa,
D. S. Samuels, and N. W. Charon.
2000.
Borrelia burgdorferi periplasmic flagella have both skeletal and motility functions.
Proc. Natl. Acad. Sci. USA
97:10899-10904 |
| 18. | Nadelman, R. B., and G. P. Wormser. 1998. Lyme borreliosis. Lancet 352:557-565[CrossRef][Medline]. |
| 19. |
Norris, S. J.,
C. J. Carter,
J. K. Howell, and A. G. Barbour.
1992.
Low-passage-associated proteins of Borrelia burgdorferi B31: characterization and molecular cloning of OspD, a surface-exposed, plasmid-encoded lipoprotein.
Infect. Immun.
60:4662-4672 |
| 20. | Norris, S. J., J. K. Howell, S. A. Garza, M. S. Ferdows, and A. G. Barbour. 1995. High- and low-infectivity phenotypes of clonal populations of in vitro-cultured Borrelia burgdorferi. Infect. Immun. 63:2206-2212[Abstract]. |
| 21. |
Probert, W. S., and R. B. Lefebvre.
1994.
Protection of C3H/HeN mice from challenge with Borrelia burgdorferi through active immunization with OspA, OspB or OspC but not OspD or the 83-kilodalton antigen.
Infect. Immun.
62:1920-1926 |
| 22. |
Purser, J. E., and S. J. Norris.
2000.
Correlation between plasmid content and infectivity in Borrelia burgdorferi.
Proc. Natl. Acad. Sci. USA
97:13865-13870 |
| 23. |
Rosa, P.,
D. S. Samuels,
D. Hogan,
B. Stevenson,
S. Casjens, and K. Tilly.
1996.
Directed insertion of a selectable marker into a circular plasmid of Borrelia burgdorferi.
J. Bacteriol.
178:5946-5953 |
| 24. |
Sadziene, A.,
A. G. Barbour,
P. A. Rosa, and D. D. Thomas.
1993.
An OspB mutant of Borrelia burgdorferi has reduced invasiveness in vitro and reduced infectivity in vivo.
Infect. Immun.
61:3590-3596 |
| 25. |
Schwan, T. G.,
W. Burgdorfer, and C. F. Garon.
1988.
Changes in infectivity and plasmid profile of the Lyme disease spirochete, Borrelia burgdorferi, as a result of in vitro cultivation.
Infect. Immun.
56:1831-1836 |
| 26. |
Schwan, T. G.,
J. Piesman,
W. T. Golde,
M. C. Dolan, and P. A. Rosa.
1995.
Induction of an outer surface protein on Borrelia burgdorferi during tick feeding.
Proc. Natl. Acad. Sci. USA
92:2909-2913 |
| 27. | Seiler, K. P., and J. J. Weis. 1996. Immunity to Lyme disease: protection, pathology and persistence. Curr. Opin. Immunol. 8:503-509[CrossRef][Medline]. |
| 28. | Simpson, W. J., C. F. Garon, and T. G. Schwan. 1990. Analysis of supercoiled circular plasmids in infectious and non-infectious Borrelia burgdorferi. Microb. Pathog. 8:109-118[CrossRef][Medline]. |
| 29. |
Stevenson, B.,
J. L. Bono,
A. Elias,
K. Tilly, and P. Rosa.
1998.
Transformation of the Lyme disease spirochete Borrelia burgdorferi with heterologous DNA.
J. Bacteriol.
180:4850-4855 |
| 30. | Stewart, P., R. Thalken, J. Bono, and P. Rosa. 2001. Isolation of a circular plasmid region sufficient for autonomous replication and transformation of infectious Borrelia burgdorferi. Mol. Microbiol 39:714-722[CrossRef][Medline]. |
| 31. | Xu, Y., C. Kodner, L. Coleman, and R. C. Johnson. 1996. Correlation of plasmids with infectivity of Borrelia burgdorferi sensu stricto type strain B31. Infect. Immun. 64:3870-3876[Abstract]. |
| 32. | Yang, X., M. S. Goldberg, T. G. Popova, G. B. Schoeler, S. K. Wikel, K. E. Hagman, and M. V. Norgard. 2000. Interdependence of environmental factors influencing reciprocal patterns of gene expression in virulent Borrelia burgdorferi. Mol. Microbiol. 37:1470-1479[CrossRef][Medline]. |
| 33. | Zhang, J. R., J. M. Hardham, A. G. Barbour, and S. J. Norris. 1997. Antigenic variation in Lyme disease borreliae by promiscuous recombination of Vmp-like sequence cassettes. Cell 89:275-285[CrossRef][Medline]. |
| 34. |
Zhang, J. R., and S. J. Norris.
1998.
Kinetics and in vivo induction of genetic variation of vlsE in Borrelia burgdorferi.
Infect. Immun.
66:3689-3697 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|